NCT02210715View on ClinicalTrials.gov

Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

January 30, 2019

Study Completion Date

January 30, 2023

Conditions
HIVFatty LiverNonalcoholic Steatohepatitis
Interventions
DRUG

Isentress.

28 subjects will change from their normal cART treatment to Raltegravir, which will be given at the standard dose of 400 mg p.o. b.i.d. for 24 months.

OTHER

Continue usual antiretroviral therapy

28 subjects will continue with their normal cART treatment, as prescribed by their treating physician.

Trial Locations (1)

Unknown

McGill University Health Center, Montreal

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER

NCT02210715 - Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients | Biotech Hunter | Biotech Hunter